Iron Drugs Market by Product, Application - Global Forecast 2023-2030

List of Tables

The Iron Drugs Market is projected to reach USD 4.16 billion by 2030 from USD 2.50 billion in 2022, at a CAGR of 6.53% during the forecast period.

Global Iron Drugs Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 2.50 billion
Estimated Year Value [2023]	USD 2.66 billion
Forecast Year Value [2030]	USD 4.16 billion
CAGR (%)	6.53%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Iron Drugs Market.

Based on Product, market is studied across Ferric Carboxymaltose, Iron Dextran, and Iron Sucrose. The Iron Dextran is projected to witness significant market share during forecast period.

Based on Application, market is studied across Cancer, Chronic Kidney Disease, and Inflammatory Bowel Disease. The Chronic Kidney Disease is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Iron Drugs Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Iron Drugs Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Iron Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accrufer, Akebia Therapeutics, Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Aqunova Pharma Private Limited, Astraea Life Sciences Pvt Ltd., Bluebird Bio, Inc., Cadila Pharmaceuticals Ltd., Corona Remedies Pvt Ltd., Covis Pharma GmbH, Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Global Calcium Pvt.Ltd, GSK PLC, Gujarat Terce Laboratories Ltd., Lupin Ltd., Pfizer Inc., Pharmacosmos A/S, Pieris Pharmaceuticals, Inc., Sanofi S.A., Solitaire Pharmacia Pvt. Ltd., Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Company Limited.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Iron Drugs Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Iron Drugs Market?

3. What is the competitive strategic window for identifying opportunities in the Iron Drugs Market?

4. What are the latest technology trends and regulatory frameworks in the Iron Drugs Market?

5. What is the market share of the leading vendors in the Iron Drugs Market?

6. Which modes and strategic moves are suitable for entering the Iron Drugs Market?

Product Code: MRR-F6513A06BF17

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Iron Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rise in the prevalence of iron disorders and deficiencies
  - 5.1.1.2. Growing awareness regarding the availability of iron supplements
  - 5.1.1.3. Government initiatives to deliver iron drugs to children and pregnant women
- 5.1.2. Restraints
  - 5.1.2.1. High cost and incidences of product recall
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in manufacturing of iron drugs
  - 5.1.3.2. Significant investment to accelerate iron drug manufacturing
- 5.1.4. Challenges
  - 5.1.4.1. Adverse effects associated with iron drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Iron Drugs Market, by Product

6.1. Introduction
6.2. Ferric Carboxymaltose
6.3. Iron Dextran
6.4. Iron Sucrose

7. Iron Drugs Market, by Application

7.1. Introduction
7.2. Cancer
7.3. Chronic Kidney Disease
7.4. Inflammatory Bowel Disease

8. Americas Iron Drugs Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Iron Drugs Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Iron Drugs Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. AbbVie Inc.
- 12.1.2. Accrufer
- 12.1.3. Akebia Therapeutics, Inc.
- 12.1.4. Alembic Pharmaceuticals Limited
- 12.1.5. Alkem Laboratories Ltd.
- 12.1.6. Aqunova Pharma Private Limited
- 12.1.7. Astraea Life Sciences Pvt Ltd.
- 12.1.8. Bluebird Bio, Inc.
- 12.1.9. Cadila Pharmaceuticals Ltd.
- 12.1.10. Corona Remedies Pvt Ltd.
- 12.1.11. Covis Pharma GmbH
- 12.1.12. Dr. Reddy's Laboratories
- 12.1.13. Emcure Pharmaceuticals
- 12.1.14. Glenmark Pharmaceuticals Ltd.
- 12.1.15. Global Calcium Pvt.Ltd
- 12.1.16. GSK PLC
- 12.1.17. Gujarat Terce Laboratories Ltd.
- 12.1.18. Lupin Ltd.
- 12.1.19. Pfizer Inc.
- 12.1.20. Pharmacosmos A/S
- 12.1.21. Pieris Pharmaceuticals, Inc.
- 12.1.22. Sanofi S.A.
- 12.1.23. Solitaire Pharmacia Pvt. Ltd.
- 12.1.24. Sun Pharmaceutical Industries Limited
- 12.1.25. Takeda Pharmaceutical Company Limited
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing